← Back to Search

Targeted Therapy

Alectinib Pharmacogenomics for Lung Cancer (Drugs-SNPs Trial)

Phase 2 & 3
Waitlist Available
Led By Han Xu, M.D., Ph.D.
Research Sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 weeks
Awards & highlights

Drugs-SNPs Trial Summary

This trial studies gene changes and how they affect drug response in NSCLC patients.

Who is the study for?
Adults over 22 with non-small cell lung cancer (NSCLC) who can undergo a lung tissue biopsy and have not used other anti-cancer therapies. They must be in good health otherwise, able to sign consent, and not pregnant or breastfeeding. Those with serious allergies, bleeding tendencies, multiple cancers, or severe illnesses cannot join.Check my eligibility
What is being tested?
The study is looking at how genetic differences affect the way Alectinib works for NSCLC treatment. It involves precise gene sequencing to understand this relationship better and will compare usual Alectinib use against a study-specific approach.See study design
What are the potential side effects?
Alectinib may cause side effects like liver issues, kidney problems, slow heartbeat, muscle pain or weakness; however specific side effects related to genetic variations are being studied.

Drugs-SNPs Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measure and Report Alectinib Drug Targets' SNP Genotypes which are effectiveness-associated, and which are risk-associated.

Drugs-SNPs Trial Design

2Treatment groups
Experimental Treatment
Group I: Alectinib - UsualExperimental Treatment1 Intervention
Usual ALECENSA - Alectinib Chemotherapy (NDC...01) Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily Usual Approach Group (NDC...01) ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily
Group II: Alectinib - StudyExperimental Treatment1 Intervention
Study ALECENSA - Alectinib Chemotherapy (NDC...86) Study ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily Study Approach Group (NDC...86) ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily

Find a Location

Who is running the clinical trial?

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairLead Sponsor
5 Previous Clinical Trials
1,840 Total Patients Enrolled
Han Xu, M.D., Ph.D.Principal InvestigatorMedicine Invention Design, Inc. - IORG0007849
Han Xu, MD/PhD/FAPCRPrincipal InvestigatorMedicine Invention Design, Inc. - IORG0007849
1 Previous Clinical Trials
600 Total Patients Enrolled

Media Library

Alectinib (Targeted Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05987956 — Phase 2 & 3
Non-Small Cell Lung Cancer Research Study Groups: Alectinib - Usual, Alectinib - Study
Non-Small Cell Lung Cancer Clinical Trial 2023: Alectinib Highlights & Side Effects. Trial Name: NCT05987956 — Phase 2 & 3
Alectinib (Targeted Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05987956 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can I partake in this trial given my current health status?

"This trial, which is seeking to enrol 600 participants, necessitates that prospective candidates must have been diagnosed with non-small cell lung cancer and fall within the age range of 22 to 75."

Answered by AI

Could eligible patients still participate in this clinical trial currently?

"According to clinicialtrials.gov, this medical experiment has ceased actively seeking participants; the study was first posted on September 28th 2023 and its latest update occurred on August 4th 2023. However, there are still 1972 distinct clinical trials that could use your help right now."

Answered by AI

Are octogenarians permitted to participate in the current research experiment?

"This trial only admits participants aged 22 to 75 years old. For those under 18 and over 65, there are 43 studies and 1965 studies respectively."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair 2024. "Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05987956.
~400 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top